Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.47, $0.24 better than the analyst estimate of $1.23. Revenue for the quarter came in at $557.9 million versus the consensus estimate of $583.12 million.

GUIDANCE:

Amedisys sees FY2022 revenue of $2.29-2.31 billion, versus the consensus of $2.35 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.